Mirador Biomedical Seeks FDA Nod
Seattle-based Mirador Biomedical said today it has filed for FDA clearance to start selling a device that helps medical professionals tell the difference between a vein or an artery as a catheter gets inserted. More than 6 million central venous procedures are done each year in the U.S., and thousands of people suffer severe injuries or death when a catheter is improperly inserted, the company says. The Mirador technology is designed to provide a quantitative pressure measurement to avoid that problem. The company, which raised $1.1 million in March from WRF Capital, Summit Capital, and angel investors, is led by CEO Karl Schmidt, who previously ran global marketing at Northstar Neuroscience.